Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
Related Articles
Balancing cancer care and holiday expectations
Social workers at Fox Chase Cancer Center share tips for managing what everyone hopes for and what’s possible for the patient.
View From the Other Side of the Stethoscope: Simone Biles’… : Oncology Times
An abstract is unavailable.
Findings for Zidesamtinib in Advanced ROS1+ NSCLC and Other Solid Tumors
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Oncologists Discuss a Second-Generation BTK for Relapsed/Refractory CLL
During a Case-Based Roundtable® event, Daniel A. Ermann, MD, discussed evaluation and treatment for a patient with relapsed chronic lymphocytic leukemia after receiving venetoclax and obinutuzumab.
Less Common Molecular Alterations in pLGG and Testing Recommendations
The panel examines less prevalent molecular alterations in pediatric low-grade gliomas (pLGG), with a particular focus on BRAF mutations, discussing their characteristics and implications for…
First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma
Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.
Durvalumab Shows Few High-Grade AEs in Cutaneous T-Cell Lymphoma
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Top Cancer Research Advances at MSK in 2024
MSK researchers continued to make strides against cancer in 2024. Learn about some of their top discoveries.
AI helps doctors identify precancerous pancreatic cysts
Finding pancreatic cancer early and predicting disease aggressiveness are critical for increasing long-term survival. With no universal pancreatic cancer
ALK TKI Earns FDA Approval
The ALK tyrosine kinase inhibitor (TKI) ensartinib (Ensacove; Xcovery) was approved for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC). The…
